Prostate Cancer Early Detection, Version 1.2014

The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for men choosing to participate in an early detection program for prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Overall, the 2014 update represents a more streamlined and concise set of recommendations. The panel stratified the age ranges at which initiating testing for prostate cancer should be considered. Indications for biopsy include both a cutpoint and the use of multiple risk variables in combination. In addition to other biomarkers of specificity, the Prostate Health Index has been included to aid biopsy decisions in certain men, given recent FDA approvals. (J Natl Compr Canc Netw 2014;12:1211–1219) Prostate Cancer Early Detection, Version 1.2014 1212 NCCN Guidelines Insights C E © JNCCN—Journal of the National Comprehensive Cancer Network | Volume 12 Number 9 | September 2014 Disclosure of Relevant Financial Relationships Editor: Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships. CE Authors: Deborah J. Moonan, RN, BSN, Director, Continuing Education & Grants, NCCN, has disclosed that she has no relevant financial relationships. Ann Gianola, MA, Manager, Continuing Education & Grants, NCCN, has disclosed that she has no relevant financial relationships. Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships. Individuals Who Provided Content Development and/or Authorship Assistance: Peter R. Carroll, MD, MPH, Panel Chair, has disclosed the following relationships with commercial interests: grant/research support from Genomic Health, Inc. Consultant fees/honoraria from Intuitive Surgical, Inc.; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc; and Teva Pharmaceutical Industries Ltd. J. Kellogg Parsons, MD, MHS, Panel Vice-Chair, has disclosed that he has no relevant financial relationships. William J. Catalona, MD, Panel Member, has disclosed the following relationships with commercial interests: consultant, researcher, and speaker for Beckman Coulter, Inc. Consultant and investigator for deCODE genetics. Consultant, investigator, and co-inventor for Ohmx Corporation. Paul Maroni, MD, Panel Member, has disclosed that he has no relevant financial relationships. Andrew J. Vickers, PhD, Panel Member, has disclosed the following relationships with commercial interests: scientific advisor for GenomeDx Biosciences Inc.; Genomic Health, Inc.; and Ringful Health LLC. Grant/research support from GlaxoSmithKline plc. Royalty income from Arctic Partners. Dorothy A. Shead, MS, Guidelines Coordinator, has disclosed that she has no relevant financial relationships. Maria Ho, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships. Supported by educational grants from Eisai, Inc.; Millennium: The Takeda Oncology Company; Teva Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.; Celgene Corporation; Endo Pharmaceuticals and HealthTronics; Genentech; and ARIAD Pharmaceuticals, Inc. NCCN: Continuing Education Accreditation Statement This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer. There is no fee for this article. The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians. NCCN designates this journalbased CE activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center`s Commission on Accreditation. This activity is accredited for 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity. National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NCCN designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers. This is a knowledge-based activity. UAN: 0836-0000-14-009-H01-P All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/53069; and 4) view/print certificate. Release date: September 5, 2014; Expiration date: September 5, 2015 Learning Objectives: Upon completion of this activity, participants will be able to: • Integrate into professional practice the updates to NCCN Guidelines for Prostate Cancer Early Detection • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Prostate Cancer Early